| Description | VV116 (JT001) is a selective and orally active nucleoside antiviral agent against respiratory syncytial virus (RSV) and SARS-CoV-2 infection. |
| In vitro | VV116 (0-1000 μM) 在 A549 细胞中抑制 RSV 的复制，其 EC50 为 1.20 μM，CC50 为 95.92 μM，选择性指数 (SI) 为 80[2]。 |
| In vivo | 在Balb/c小鼠中，VV116（25、50及100 mg/kg；口服）显示出良好的药代动力学特性和安全性。VV116（25、50及100 mg/kg；口服）展示出更强的活性，在50 mg/kg时能将病毒滴度降至检测限以下，并在RSV感染后减轻肺损伤[2]。 |
| Synonyms | GS-621763-d1, JT001 |
| molecular weight | 502.54 |
| Molecular formula | C24H30DN5O7 |
| CAS | 2647442-33-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 245 mg/mL (419.92 mM), Sonication is recommended. |
| References | 1. Qian HJ, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects [published online ahead of print, 2022 Mar 16]. Acta Pharmacol Sin. 2022;1-9. 2. Zhang R, et al. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther. 2022;7(1):123. Published 2022 Apr 16. |